Merck doubles down on NGM Bio pact but culls obesity drug

Back in 2015, Merck penned a $450 million R&D pact with little NGM Bio for a broad range of early-stage assets. Today, Merck is extending this pact, although it’s also tidying up shop with the culling of one particular therapy that didn’t work out.